HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $9 to $6.
Follow the latest LifeMD, Inc. (LFMD) news and market headlines alongside the live LFMD price. Stay informed on what's moving LFMD.
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $9 to $6.
LifeMD announced strategic shifts including direct pharmacy partnerships with Eli Lilly and Novo Nordisk for GLP-1 medications, a major enterprise collaboration with AT&T providing access to 100 million customers, and lower introductory pricing that increased multi-month subscriptions from 25% to 85%. The company expects flat overhead while patient volume grows, positioning it well in the virtual care and pharmacy market.
Lake Street analyst Ryan Meyers maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $5 to $3.
Gainers Cerenome (NASDAQ:CNSY) shares rose 39.5% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $5.8 million. As per the press release, Q3 earnings came out today. SBC
Mizuho analyst Steven Valiquette maintains LifeMD (NASDAQ:LFMD) with a Outperform and lowers the price target from $7 to $6.
Gainers SELLAS Life Sciences Gr (NASDAQ:SLS) stock rose 19.6% to $9.6 during Friday's pre-market session. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q3 earnings report
LifeMD (LFMD) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.14 loss by 21.43%, but missed revenue expectations with $44.63 million versus the estimated $48.81 million. The company's stock has declined 47.8% year-to-date compared to the S&P 500's 11.3% gain. With a Zacks Rank #3 (Hold) rating, the stock is expected to perform in line with the market.
LifeMD (NASDAQ:LFMD) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 57.14 percent decrease over losses of $(0.07) per share from the same
LifeMD (NASDAQ:LFMD) lowers FY2026 sales outlook from $205.500 million-$212.500 million to $188.000 million-$191.000 million vs $207.582 million estimate.
LifeMD (NASDAQ:LFMD) sees Q4 sales of $46.000 million-$49.000 million vs $61.318 million analyst estimate.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to LFMD, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.